Cargando…

Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells

Clinical studies evaluating targeted BRAFV600E inhibitors in advanced thyroid cancer patients are currently underway. Vemurafenib (BRAFV600E inhibitor) monotherapy has shown promising results thus far, although development of resistance is a clinical challenge. The objective of this study was to cha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanly, Elyse K., Tuli, Neha Y., Bednarczyk, Robert B., Suriano, Robert, Geliebter, Jan, Moscatello, Augustine L., Darzynkiewicz, Zbigniew, Tiwari, Raj K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890996/ https://www.ncbi.nlm.nih.gov/pubmed/26735176 http://dx.doi.org/10.18632/oncotarget.6779

Ejemplares similares

mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib
por: Hanly, Elyse K., et al.
Publicado: (2015)

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype
por: Hanly, Elyse K, et al.
Publicado: (2014)

Gene master regulators of papillary and anaplastic thyroid cancers
por: Iacobas, Dumitru A., et al.
Publicado: (2017)

Macrophage inflammatory factors promote epithelial-mesenchymal transition in breast cancer
por: Bednarczyk, Robert B., et al.
Publicado: (2018)

PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells
por: George, Andrea L., et al.
Publicado: (2015)

Biguanides and targeted anti-cancer treatments
por: Hanly, Elyse K., et al.
Publicado: (2015)

MEG3 Expression Indicates Lymph Node Metastasis and Presence of Cancer-Associated Fibroblasts in Papillary Thyroid Cancer
por: Dadafarin, Sina, et al.
Publicado: (2022)

Androgen Receptor Activation Induces Senescence in Thyroid Cancer Cells
por: Gupta, Anvita, et al.
Publicado: (2023)

Ex Vivo Derived Primary Melanoma Cells: Implications for Immunotherapeutic Vaccines
por: Suriano, Robert, et al.
Publicado: (2013)

Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor
por: Chik, Constance L, et al.
Publicado: (2021)

Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
por: Aylwin, Simon J. B., et al.
Publicado: (2015)

Estrogen Induced Metastatic Modulators MMP-2 and MMP-9 Are Targets of 3,3′-Diindolylmethane in Thyroid Cancer
por: Rajoria, Shilpi, et al.
Publicado: (2011)

Molecular target based combinational therapeutic approaches in thyroid cancer
por: Rajoria, Shilpi, et al.
Publicado: (2012)

Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells
por: Li, Hongxia, et al.
Publicado: (2022)

Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib
por: Hu, Linfei, et al.
Publicado: (2022)

Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mTOR pathway
por: Wang, Lei, et al.
Publicado: (2022)

Androgen Activity Is Associated With PD-L1 Downregulation in Thyroid Cancer
por: O’Connell, Timmy J., et al.
Publicado: (2021)

Running m(o)TOR with the brakes on leads to catastrophe at mitosis
por: Darzynkiewicz, Zbigniew
Publicado: (2012)

Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling
por: Halicka, H. Dorota, et al.
Publicado: (2012)

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling
por: Tan, Yufan, et al.
Publicado: (2021)

mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cells
por: Brown, Robert A., et al.
Publicado: (2019)

Scurvy in a patient on vemurafenib
por: Gerstenblith, Meg R., et al.
Publicado: (2014)

Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma
por: Temblador, Arturo, et al.
Publicado: (2022)

Racially Disparate Expression of mTOR/ERK-1/2 Allied Proteins in Cancer
por: Mishra, Sanjay, et al.
Publicado: (2021)

Normalizing a hyperactive mTOR initiates muscle growth during obesity
por: Williamson, David L., et al.
Publicado: (2011)

Depdc5 knockdown causes mTOR‐dependent motor hyperactivity in zebrafish
por: de Calbiac, Hortense, et al.
Publicado: (2018)

ubtor Mutation Causes Motor Hyperactivity by Activating mTOR Signaling in Zebrafish
por: Wang, Tiantian, et al.
Publicado: (2021)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013)

Complete remission of critical neurohistiocytosis by vemurafenib
por: Euskirchen, Philipp, et al.
Publicado: (2015)

Delayed-onset vemurafenib-induced panniculitis
por: Vance, Stephen L., et al.
Publicado: (2017)

A Rare Cause of Uveitis: Vemurafenib
por: Sızmaz, Selçuk, et al.
Publicado: (2018)

Silencing FOXP2 reverses vemurafenib resistance in BRAF(V600E) mutant papillary thyroid cancer and melanoma cells
por: Jiang, Suyuan, et al.
Publicado: (2022)

The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B
por: Jiang, Shi-Long, et al.
Publicado: (2021)

Adverse Effects of Vemurafenib on Skin Integrity: Hyperkeratosis and Skin Cancer Initiation Due to Altered MEK/ERK-Signaling and MMP Activity
por: Tham, Marius, et al.
Publicado: (2022)

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
por: Cui, Hongmei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4ek8j4eiqhm0kfra8ljivef8mt